The Present Status of Streptococcus Biologic Products in the Prevention and Treatment of Scarlet Fever.. Ann Intern Med. 1930;4:643-644. doi: 10.7326/0003-4819-4-6-643_4
Download citation file:
Published: Ann Intern Med. 1930;4(6):643-644.
This content is PDF only. Please click on the PDF icon to access.
In the Conference of Health Officers and the United States Public Health Service in 1926, it was the general opinion that the intradermal reaction to scarlet-fever streptococcus toxin is a fairly dependable measure of the susceptibility of the individual tested. The majority of the individuals giving a positive reaction can be effectively immunized by the proper use of scarlet-fever streptococcus toxin. The use of scarlet-fever streptococcus antitoxin, either for passive immunization, or for the treatment of the individual with scarlet-fever, is not yet founded on sufficient clinical data to permit a mature opinion as to the efficacy of this form
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, Streptococcal Infections.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only